Genetic engineering of the bioproduction,
immunogen optimization
Enhanced therapeutic efficacy of GH-pAb validated pharmaceutical development, stability for more than 3 years
Translational development program experience with 3 products in clinic.
Oncology
Immunology
Infectius (virus, bacteria)
Others
A clinical stage Biotech
XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in several indications. Our patented technological platform is built on our expertise in immunology and therapeutics. We develop innovative approaches in immunotherapy with our platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are addressing major therapeutic needs in various domains, including oncology, immunosuppression, viral and bacterial infections. XENOTHERA’s platform allows short-time development thanks to our validated saled-up GMP platform, our in-house bioproduction facility, our clinical experience (400 patients have received GH-pAb today), our mastery of antigens and our regulatory experience. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market, XAB05, a preventive anti- multidrug resistant bacteria GH-pAb, XAV19 an anti-COVID antibody dedicated to patients with moderate disease. XENOTHERA has accumulated preclinical evidence for the therapeutic effect of its oncology GH-pAbs. Two products will be in clinic in oncology in 2023, XON7, its lead pan-cancer targeting solid tumors and LIS22 in peripheral T-Cell lymphoma.
EU CTA
XON7
FDA ODD
(T lymphoma)LIS22
Clinical efficacy
XAV19
POC in Vivo
(PTCL)Toxicology completion
XON7
EMA Scientific Advice
(SOT)LIS1
EMA ODD (SOT)
Phase I/II
CompletionPhase I
CompletionXAB05
Series B
Phase I CTA
XAB05
Phase II
Phase II/IIIPhase I/II
XAB05 & XON POC in vivoPreclinical package
Series ASeed funding
Proof of concept
LIS1
Company creation
Pipeline
Products in development

Latest
News
[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment
November 27, 2023. # Download our press release (english version) # Télécharger...
More[Press Release] French biotech announces its therapeutic potential for oxygen-free patients
October 25, 2023. # Download our press release (english version) # Télécharger...
More[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.
September 12, 2023. # Download our press release (english version) # Télécharger...
MoreRelated
scientific papers
XENOTHERA is a start-up in biotechnology, developing innovative immunological treatments, specialized in oncology, and other therapeutic domains.
Investors already trusted us since creation by funding the company more than 46M€. Our products are expected to address unsolved major public health issues.
Our vision is to bring new approaches to the patients, as
INNOVATIVE LAB FOR RESPONSIVE CARE .
To contact us, use the form or see our full contact below:
XENOTHERA
21 rue La Nouë Bras de Fer – 44200 Nantes – France
To work with us: careers@xenothera.com
Press Contact: IZsoGOOD – Ingrid Zémor – xenothera@izsogood.co